$XBI $76.80 | -0.34%
Table of Contents:
Covid Updates
#BNTX +7.2% Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron . source
Pipeline Updates
#EVFM +187.7%
#KZR -4.3% (+109% aftr mrkt) Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis
#AXSM +51.4%
#IFRX +38.3%
#TCRT +17.3% Alaunos Therapeutics and the National Cancer Institute Extend Cooperative Research and Development Agreement for Development of Personalized TCR-T Cell Therapies to 2025. source
#AGRX +10.4%
#ELYM +6.3% Eliem Therapeutics Announces Last Patient Completed Dosing in Phase 2a Study of ETX-810 in Patients with Lumbosacral Radicular Pain (LSRP)
#ADIL +3.4% Adial Pharmaceuticals Announces Database Lock for the ONWARDâ„¢ Phase 3 Clinical Trial. source
#EIGR +3.0% Eiger BioPharmaceuticals Announces Results from Multiple Presentations at the European Association for the Study of the Liver (EASL) International Liver Congressâ„¢ 2022
#NXTC +2.8% NextCure Presented NC410 Data at the Extracellular Matrix (ECM) Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM. source
#BEAM +1.4% Beam Therapeutics to Present First Research Highlighting Approach to Develop Non-Genotoxic Conditioning Regimens for Patients with Sickle Cell Disease Ahead of Autologous Transplant. source
#BBIO +1.1% BridgeBio Pharma Announces Positive Phase 1 Data and Phase 2/3 Trial Design for BBP-711, a Potentially Best-In-Class GO Inhibitor for Primary Hyperoxaluria Type 1 (PH1) and Recurrent Kidney Stone Formers. source
#IMCR +0.5% Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™. source
#IONS +0.2% Ionis announces presentation of positive Phase 2b data for chronic hepatitis B treatment at the EASL International Liver Congressâ„¢. source
#GILD -0.4% Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor
#SLS -1.7% SELLAS Life Sciences Provides Clinical Update for GFH009 Ongoing Phase 1 Clinical Trial. source
#ARWR -2.2% Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine. source
#AKRO -2.9% Akero Therapeutics Presents Analysis at the 2022 International Liver Congress Showing that Efruxifermin Improved Histopathology and Markers of Liver Injury Across PNPLA3 Genotypes in Patients with NASH Fibrosis . source
#TNXP -5.4% Tonix Pharmaceuticals Announces Trial Design of New Phase 2 Clinical Study of TNX-1300 for Cocaine Intoxication. source
#ABUS -5.6% Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congressâ„¢ 2022 and Provides AB-836 Clinical Update. source
#HOWL -6.8%
#MDGL -9.8% Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™. source
#RLAY -10.5% Relay Therapeutics Discloses Anticipated Registrational Path for RLY-4008 in Cholangiocarcinoma and Growing Breast Cancer Franchise at Virtual Analyst and Investor Event. source
#SPRO -10.6% Spero Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Tebipenem HBr New Drug Application
#NUVB -13.1% Nuvation Bio Announces FDA Partial Clinical Hold for Phase 1 Study of NUV-422 in Solid Tumors. source
#SIGA -16.6%
#ENOB -21.9%
Want to get weekly catalyst updates?
*We never spam you - unsubscribe anytime*
Business Updates
#XENE +1.5% Xenon Pharmaceuticals Announces Closing of $287.5 Million Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Posted by FS/JM